WHAT IS CLAIMED IS:

1	1. A method for determining whether a subject has or is predisposed for			
2	mood disorder, the method comprising the steps of:			
3	(i) obtaining a biological sample from a subject;			
4	(ii) contacting the sample with a reagent that selectively associates with a			
5	polynucleotide or polypeptide encoded by a nucleic acid that hybridizes under stringent			
6	conditions to a nucleotide sequence of Table 2, 3, or 4; and			
7	(iii) detecting the level of reagent that selectively associates with the sample,			
8	thereby determining whether the subject has or is predisposed for a mood disorder.			
1	2. The method of claim 1, wherein the reagent is an antibody.			
1	3. The method of claim 1, wherein the reagent is a nucleic acid.			
1	4. The method of claim 1, wherein the reagent associates with a			
2	polynucleotide.			
1	5. The method of claim 1, wherein the regent associates with a			
2	polypeptide.			
1	6. The method of claim 1, wherein the level of reagent that associates			
2	with the sample is different from a level associated with humans without a mood disorder.			
1	7. The method of claim 1, wherein the biological sample is obtained from			
2 .	amniotic fluid.			
1	8. The method of claim 1, wherein the mood disorder is selected from the			
2	group consisting of bipolar disorder I, bipolar disorder II, and major depression disorder.			
1	9. The method of claim 6, wherein the level of reagent that associates			
2	with the sample is higher than a level associated with humans without a mood disorder.			
1	10. The method of claim 6, wherein the level of reagent that associates			
2	with the sample is lower than a level associated with humans without a mood disorder.			
1	11. A method of identifying a compound for treatment or prevention of a			
2	mood disorder, the method comprising the steps of:			

3	(i) contacting the compound with a polypeptide, the polypeptide encoded by a				
4	polynucleotide that hybridizes under stringent conditions to a nucleic acid sequence				
5	comprising a nucleotide sequence of Table 2, 3, or 4; and				
6	(ii) determining the functional effect of the compound upon the polypeptide,				
7	thereby identifying a compound for treatment or prevention of a mood disorder.				
1	1	2.	The method of claim 11, wherein the contacting step is performed in		
2	vitro.				
1	1	3.	The method of claim 11, wherein the polypeptide is expressed in a cell		
2	and the cell is contacted with the compound.				
1	1	4.	The method of claim 11, the mood disorder is selected from the group		
2			disorder I, bipolar disorder II, and major depression disorder.		
1	1	5.	The method of claim 11, further comprising administering the		
2		compound to an animal and determining the effect on the animal.			
1	1	6.	The method of claim 15, wherein the determining step comprises		
2	testing the anim				
	Ū				
1		7.	A method of identifying a compound for treatment of a mood disorder		
2	in a subject, the method comprising the steps of:				
3	(i) contacting the compound to a cell, the cell comprising a polynucleotide that				
4	hybridizes under stringent conditions to a nucleotide sequence of Table 2, 3, or 4; and				
5	(ii) selecting a compound that modulates expression of the polynucleotide,				
6	thereby identifying a compound for treatment of a mood disorder.				
1	1	8.	The method of claim 17, wherein the expression of the polynucleotide		
2	is enhanced.				
1	1	9.	The method of claim 17, wherein the expression of the polynucleotide		
2	is decreased.				
1	2	20.	The method of claim 17, further comprising administering the		
2	compound to an animal and determining the effect on the animal.				

		·		
1	21.	The method of claim 20, wherein the determining step comprises		
2	testing the animal's mental function.			
1	22.	The method of claim 17, wherein the mood disorder is selected from		
2	the group consisting	of bipolar disorder I, bipolar disorder II, and major depression disorder		
1	23.	A method of treating a mood disorder in a subject, the method		
2	comprising the step	of administering to the subject a therapeutically effective amount of a		
3	compound identified using the method of claim 11 or claim 17.			
1	24.	The method of claim 23, wherein the mood disorder is selected from		
2	the group consisting	of bipolar disorder I, bipolar disorder II, and major depression disorder		
1	25.	The method of claim 23, wherein the compound is a small organic		
2	molecule.			
1	26.	A method of treating a mood disorder in a subject, the method		
2	comprising the step of administering to the subject a therapeutically effective amount of a			
3	polypeptide, the polypeptide encoded by a polynucleotide that hybridizes under stringent			
4	conditions to a nucleotide sequence of Table 2, 3, or 4.			
1	27.	The method of claim 26, wherein the mood disorder is selected from		
2	the group consisting	of bipolar disorder I, bipolar disorder II, and major depression disorder		
1	28.	A method of treating a mood disorder in a subject, the method		
2	comprising the step	of administering to the subject a therapeutically effective amount of a		
3	nucleic acid, wherein the nucleic acid hybridizes under stringent conditions to a nucleotide			
1	sequence of Table 2.3 or 4			

The method of claim 28, wherein the mood disorder is selected from

the group consisting of bipolar disorder I, bipolar disorder II, and major depression disorder.

29.

1

2